Lonza and Integral Molecular partner on biotherapeutics
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
The new lab in the industrial town is SRL’s 4th lab in the state of Jharkhand
Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
Covaxin was earlier approved for children 12-18 years of age
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Real-world evidence from more than 850,000 hospitalized patients provides clinical insights on the use of Veklury (remdesivir) as stand of care Covid-19 treatment
This is the first major brand refresh of CanSinoBIO since its inception in 2009
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Subscribe To Our Newsletter & Stay Updated